TW200640466A - Method of treatment - Google Patents

Method of treatment

Info

Publication number
TW200640466A
TW200640466A TW095100687A TW95100687A TW200640466A TW 200640466 A TW200640466 A TW 200640466A TW 095100687 A TW095100687 A TW 095100687A TW 95100687 A TW95100687 A TW 95100687A TW 200640466 A TW200640466 A TW 200640466A
Authority
TW
Taiwan
Prior art keywords
related disorders
disorders
substance
pharmaceutically acceptable
limited
Prior art date
Application number
TW095100687A
Other languages
Chinese (zh)
Inventor
Patricia C Davis
Jeffrey M Goldstein
Scott W Grimm
Helen R Winter
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200640466A publication Critical patent/TW200640466A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating at least one symptom or condition associated with but not limited to: (1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative, Hypnotic- or Anxiolytic-Related Disorders. (2) Attention-Deficit and Disruptive Behavior Disorders. (3) Eating Disorders. (4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. (5) Impulse-Control Disorders, comprising administering an effective amount of formula I, or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.
TW095100687A 2005-01-07 2006-01-06 Method of treatment TW200640466A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786505P 2005-11-18 2005-11-18
US73786405P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
TW200640466A true TW200640466A (en) 2006-12-01

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095100687A TW200640466A (en) 2005-01-07 2006-01-06 Method of treatment

Country Status (6)

Country Link
EP (1) EP1838325A1 (en)
JP (1) JP2008526839A (en)
AR (1) AR052191A1 (en)
TW (1) TW200640466A (en)
UY (1) UY29326A1 (en)
WO (1) WO2006073360A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
NZ590616A (en) 2008-06-20 2012-09-28 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
US8389716B2 (en) 2009-01-30 2013-03-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US7071133B2 (en) * 1993-11-16 2006-07-04 Ppg Industries Ohio, Inc. Colored glass compositions and-automotive vision panels with-reduced transmitted-color shift
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US7304047B2 (en) * 2001-02-06 2007-12-04 Astrazeneca Ab Method of treating substance abuse with quetiapine
CA2502787A1 (en) * 2002-10-18 2004-04-29 Massachusetts Mental Health Institute Treating alcohol and or substance abuse by antagonizing .alpha. 2 adrenergic receptors with weak dopamine blocking
MXPA05013869A (en) * 2003-07-02 2006-02-28 Astrazeneca Ab Metabolite of quetiapine.
EP1696857A2 (en) * 2003-12-04 2006-09-06 The Research Foundation Of the City university of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
DE602004020263D1 (en) * 2003-12-22 2009-05-07 Acadia Pharm Inc AMINO-SUBSTITUTED DIARYLÄA, DREPTYCLEPTEN ANALOGUE AS MUSCARINAL AGONISTS AND METHOD FOR THE TREATMENT OF NEUROPSYCHIATRICAL DISEASES
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Also Published As

Publication number Publication date
AR052191A1 (en) 2007-03-07
WO2006073360A1 (en) 2006-07-13
EP1838325A1 (en) 2007-10-03
JP2008526839A (en) 2008-07-24
UY29326A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2004032836A3 (en) Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
MA28469B1 (en) INHIBITORS OF DIPEPTIDYL PEPTIDASE
EP2338490A3 (en) Combinations useful for the treatment of neuronal disorders
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
PT1556362E (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007006003A3 (en) Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2006017673A3 (en) Taj in neuronal function
GB0225474D0 (en) Therapeutic agents
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
DE602004014361D1 (en) USE OF OXAZOLIDINONE CHINOLIN HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
TW200640466A (en) Method of treatment
TW200616644A (en) Medicine for prevention or treatment of diabetes
DE602004015089D1 (en) PYRROLOIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THESE INGREDIENT COMPOSITIONS, AND THEIR USE AS NOOTROPIKA
DE60036122D1 (en) USE OF EPLERENONE FOR THE TREATMENT OF RESTENOSIS
TW200503726A (en) Use of dihydroimidazolones for the treatment of dogs
Bowen et al. Lithium and marijuana withdrawal
ATE326223T1 (en) METHOD OF TREATING HYPERACTIVE BLADDER
WO2005007239B1 (en) Use of dapsone as a neuroprotector in cerebral infarction
WO2007071840A3 (en) Compounds based on four aromatic rings, preparation and uses thereof
TW200630097A (en) Methods of using PDE V inhibitors for the treatment of congestive heart failure
ATE411810T1 (en) LAMINARINE OR OLIGOLAMINARIN MEDICINE FOR THE TREATMENT OF SEPTICAEMIA AND SHOCK